FindTrial
Sign In

TPI 287

DRUG12 trials

Sponsors

Cortice Biosciences, Inc., Giselle Sholler, M.D. Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Brain CancerBrain LesionsBrain MetastasesBreast CancerGeneralized Malignancy, PrimaryGlioblastoma MultiformeMedulloblastomaMelanoma

Phase 1

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
CompletedNCT00867568
Giselle ShollerMedulloblastoma, Neuroblastoma, Relapse
Start: 2009-03-31End: 2016-02-29Updated: 2024-08-06
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
TerminatedNCT01067066
M.D. Anderson Cancer CenterMelanoma
Start: 2010-02-03End: 2016-07-06Updated: 2017-07-21
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
WithdrawnNCT01340729
M.D. Anderson Cancer CenterMetastatic Melanoma
Start: 2013-09-30Updated: 2013-04-05
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
TerminatedNCT01483820
Giselle ShollerMedulloblastoma, Neuroblastoma
Start: 2011-12-31End: 2014-12-31Updated: 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
TerminatedNCT01505608
Giselle ShollerNeuroblastoma
Start: 2011-12-31End: 2014-12-31Updated: 2024-08-06
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
SuspendedNCT01933815
Cortice Biosciences, Inc.Glioblastoma Multiforme
Start: 2013-08-31End: 2025-05-31Target: 92Updated: 2023-02-22
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
TerminatedNCT02187822
H. Lee Moffitt Cancer Center and Research InstituteBrain Lesions, Brain Metastases, Generalized Malignancy, Primary
Start: 2014-10-09End: 2018-03-31Updated: 2021-02-04

Phase 2

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
TerminatedNCT00479635
Cortice Biosciences, Inc.Prostate Cancer
Start: 2007-01-31End: 2008-08-31Updated: 2014-01-22
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
TerminatedNCT00553813
Cortice Biosciences, Inc.Pancreatic Cancer
Start: 2007-10-31End: 2010-04-30Updated: 2014-01-22
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
TerminatedNCT01113463
M.D. Anderson Cancer CenterBrain Cancer
Start: 2010-04-30End: 2012-12-31Updated: 2016-10-31
TPI 287 in Breast Cancer Metastatic to the Brain
CompletedNCT01332630
M.D. Anderson Cancer CenterBreast Cancer
Start: 2011-08-16End: 2017-04-14Updated: 2018-09-20
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
TerminatedNCT02047214
Cortice Biosciences, Inc.Glioblastoma Multiforme
Start: 2014-01-31End: 2015-12-31Updated: 2018-01-31

Related Papers

Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.
Journal of Clinical Oncology2017-05-203 citations
Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.
Journal of Clinical Oncology2016-05-205 citations
ATNT-22A PHASE 1 STUDY OF TPI 287 CONCURRENT WITH FRACTIONATED STEREOTACTIC RADIOTHERAPY (FSRT) IN TREATMENT OF BRAIN METASTASES FROM ADVANCED BREAST AND NON-SMALL CELL LUNG (NSCL) CANCER
Neuro-Oncology2015-11-01
A phase I study of TPI 287 concurrent with fractionated stereotactic radiotherapy (FSRT) in treatment of brain metastases from advanced breast and non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2015-05-201 citations